SEC Form 4 · accession 0001104659-17-035349
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Harrison Talbot
Director
Period of report
May 23, 2017
Accepted (ET)
May 25, 2017 · 8:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | May 23, 2017 | S | 30 | $99.70 | D | 3,854 | D | |
| Common SharesF1,F3 | May 25, 2017 | S | 205 | $100.50 | D | 3,649 | D | |
| Common SharesF1,F4 | May 25, 2017 | S | 90 | $101.00 | D | 3,559 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- F2The price of $99.70 per common share was derived from the sale price on May 23, 2017, of $9.97 per ADS, multiplied by ten.
- F3The price of $100.50 per common share was derived from the sale price on May 25, 2017, of $10.05 per ADS, multiplied by ten.
- F4The price of $101.00 per common share was derived from the sale price on May 25, 2017, of $10.10 per ADS, multiplied by ten.